(NASDAQ: SRDX) Surmodics's forecast annual revenue growth rate of 4.41% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 59.11%.
Surmodics's revenue in 2025 is $121,575,000.On average, 4 Wall Street analysts forecast SRDX's revenue for 2026 to be $1,775,110,881, with the lowest SRDX revenue forecast at $1,687,170,395, and the highest SRDX revenue forecast at $1,846,893,197.
In 2027, SRDX is forecast to generate $1,895,224,716 in revenue, with the lowest revenue forecast at $1,820,868,532 and the highest revenue forecast at $1,950,848,860.